Research programme - adenoviral gene therapy - Shanghai Sunway BiotechAlternative Names: H-102; H100 series
Latest Information Update: 08 Oct 2015
At a glance
- Originator Shanghai Sunway Biotech
- Class Gene therapies
- Mechanism of Action P53 gene modulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 01 Jul 2015 Preclinical trials in Cancer in China (Intratumoural)